Last reviewed · How we verify
Intraduodenal quinine hydrochloride
Intraduodenal quinine hydrochloride acts as a bitter taste receptor agonist that stimulates local sensory pathways in the small intestine to modulate glucose homeostasis and metabolic function.
Intraduodenal quinine hydrochloride acts as a bitter taste receptor agonist that stimulates local sensory pathways in the small intestine to modulate glucose homeostasis and metabolic function. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Intraduodenal quinine hydrochloride |
|---|---|
| Also known as | ID QHCl |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Drug class | Bitter taste receptor agonist |
| Target | TAS2R (bitter taste receptors) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Quinine activates bitter taste receptors (TAS2Rs) located on enteroendocrine cells in the duodenum, triggering the release of incretin hormones and other metabolic regulators. This localized intestinal stimulation enhances glucose-dependent insulin secretion and improves postprandial glucose control without systemic absorption of the drug.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal distress
- Nausea
- Bitter taste sensation
Key clinical trials
- IG vs ID Bitter Administration (PHASE4)
- The Effect of Bitter Taste Receptor Agonists on The Gastrointestinal Tract, Hunger and Food Intake (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: